1-吡啶-2-基哌啶-3-羧酸

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-吡啶-2-基哌啶-3-羧酸
• 中文别名: 3,4,5,6-四氢-2H-[1,2’]联吡啶-3-甲酸
• 英文名称: 1-pyridin-1-ium-2-ylpiperidine-3-carboxylate
• 化学式: C11H14N2O2
• mdl: MFCD06738899
• 分子量: 206.24
• InChiKey: QZQCXIGVFAOJNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  53.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN<br/>[FR] COMPOSITION PHARMACEUTIQUE COMPRENANT UN DERIVE DE BENZODIAZEPINE ET UN INHIBITEUR DE LA PROTEINE DE FUSION DU VIRUS RESPIRATOIRE SYNCYTIAL
  申请人：ARROW THERAPEUTICS LTD

  公开号：WO2005089771A1

  公开（公告）日：2005-09-29

  A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.

  一种包含药用可接受载体或稀释剂以及：(a) RSV融合蛋白抑制剂；和(b) 能够抑制RSV复制的苯二氮䓬类衍生物的药物组合物被发现对RSV具有很高的活性。
• Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors
  申请人：Attenni Barbara

  公开号：US20090048228A1

  公开（公告）日：2009-02-19

  The present invention relates to compounds of formula I: or pharmaceutically acceptable salts or tautomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.

  本发明涉及以下式I的化合物：或其药用可接受的盐或互变异构体，这些化合物是组蛋白去乙酰化酶（HDAC）的抑制剂。本发明的化合物可用于治疗细胞增殖性疾病，包括癌症。此外，本发明的化合物还可用于治疗神经退行性疾病、精神分裂症和中风等其他疾病。
• Beta-secretase modulators and methods of use
  申请人：Albrecht K. Brian

  公开号：US20070185103A1

  公开（公告）日：2007-08-09

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R 3 , R 4 , R 5 , i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一类新的化合物，用于调节Beta-分泌酶酶活性和治疗Beta-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关疾病。 在一种实施方式中，该化合物具有一般式I，其中A，B，R3，R4，R5，i和j在此定义。 本发明还包括包括一种或多种I式化合物的制药组合物，以及使用这些化合物的方法，包括通过向受体注射I式化合物或包含它们的组合物来治疗AD和相关疾病。 本发明还包括II式和III式的进一步实施方式，以及用于制备本发明化合物的中间体和过程。
• Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
  申请人：Whitney James A.

  公开号：US20100160292A1

  公开（公告）日：2010-06-24

  Methods of inhibiting BTK activity by inhibiting phosphorylation of Y551 of BTK, methods of treating patients by inhibiting BTK activity by inhibiting phosphorylation of Y551 of BTK, chemical entities that bind to BTK and inhibited complexes are provided.

  提供通过抑制BTK Y551的磷酸化来抑制BTK活性的方法，提供通过抑制BTK Y551的磷酸化来治疗患者的方法，提供结合BTK并抑制复合物的化学实体。
• BETA-SECRETASE MODULATORS AND METHODS OF USE
  申请人：Albrecht Brian K.

  公开号：US20110118250A1

  公开（公告）日：2011-05-19

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R 3 , R 4 , R 5 , i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一类新型化合物，可用于调节β-分泌酶酶活性和治疗β-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关疾病。在一种实施例中，所述化合物具有一般式I，其中A、B、R3、R4、R5、i和j在此被定义。本发明还包括包括一种或多种式I化合物的制药组合物，以及使用这些化合物的方法，包括将式I化合物或包含它们的组合物用于治疗AD和相关疾病，通过将式I化合物或包含它们的组合物用于给予受试者的方法。本发明还包括式II和III的进一步实施例，以及用于制备本发明化合物的中间体和方法。